Caris Life Sciences Inc [NASDAQ: CAI] gained 0.23% on the last trading session, reaching $26.11 price per share at the time.
Caris Life Sciences Inc represents 282.10 million in outstanding shares, while the company has a total market value of $7.37 billion with the latest information. CAI stock price has been found in the range of $25.51 to $27.56.
If compared to the average trading volume of 1.06M shares, CAI reached a trading volume of 9510862 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Caris Life Sciences Inc [CAI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CAI shares is $38.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CAI stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Canaccord Genuity have made an estimate for Caris Life Sciences Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on December 02, 2025. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Outperform. The new note on the price target was released on July 14, 2025, representing the official price target for Caris Life Sciences Inc stock. Previously, the target price had yet another raise to $32, while TD Cowen analysts kept a Buy rating on CAI stock.
The Price to Book ratio for the last quarter was 15.40, with the Price to Cash per share for the same quarter was set at 2.68.
Trading performance analysis for CAI stock
Caris Life Sciences Inc [CAI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.82.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CAI stock in for the last two-week period is set at 47.39, with the RSI for the last a single of trading hit 1.76, and the three-weeks RSI is set at 1.81 for Caris Life Sciences Inc [CAI]. The present Moving Average for the last 50 days of trading for this stock 28.63, while it was recorded at 25.67 for the last single week of trading.
Caris Life Sciences Inc [CAI]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Caris Life Sciences Inc [CAI] shares currently have an operating margin of -12.38% and a Gross Margin at 59.93%. Caris Life Sciences Inc’s Net Margin is presently recorded at -105.05%.
Caris Life Sciences Inc (CAI) Capital Structure & Debt Analysis
Caris Life Sciences Inc (CAI) Efficiency & Liquidity Metrics
Based on Caris Life Sciences Inc’s (CAI) latest financial statements, the Debt-to-Equity Ratio is 0.89%, indicating its reliance on debt financing relative to shareholder equity.
Caris Life Sciences Inc (CAI) Efficiency & Liquidity Metrics
Caris Life Sciences Inc [CAI]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Caris Life Sciences Inc posted 0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.14/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.22. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CAI.
An analysis of Institutional ownership at Caris Life Sciences Inc [CAI]
There are presently around $47.70%, or 92.56%% of CAI stock, in the hands of institutional investors.
